Previous 10 | Next 10 |
2023-03-08 08:36:27 ET Fresh Tracks Therapeutics ( FRTX ) +83% on announcing positive topline results from single and multiple ascending dose parts of phase 1 study of Oral DYRK1A Inhibitor FRTX-02. Kimball International ( KBAL ) +75% HNI to acquire Kimball i...
S100P Gene Expression May Be Marker of Anti-Tumor Activity in Pancreatic Cancer In Vivo Models CARLSBAD, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLG...
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...
CARLSBAD, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...
CARLSBAD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...
Qualigen Therapeutics ( NASDAQ: QLGN ) stock rose ~15% on Tuesday after the company said that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to QN-302 to treat pancreatic cancer. "Receiving Orphan Drug Designation for our lead cancer therapeu...
CARLSBAD, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...
CARLSBAD, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...
Qualigen Therapeutics ( NASDAQ: QLGN ) has received Nasdaq notice, informing the company that it has regained compliance minimum bid price requirement and the matter is now closed. The closing bid price of the company’s common stock having been at least $1.00 per share for ...
CARLSBAD, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designatio...
News, Short Squeeze, Breakout and More Instantly...
Qualigen Therapeutics Inc. Company Name:
QLGN Stock Symbol:
NASDAQ Market:
Qualigen Therapeutics Inc. Website:
A look at the top 10 most actives in the United States American Rebel Holdings Inc. (AREB) rose 60.3% to $0.83355 on volume of 56,112,820 shares DatChat Inc. (DATS) rose 71.2% to $1.78 on volume of 33,845,116 shares Autonomix Medical Inc. (AMIX) rose 97.4% to $1.22 on volume of 33,054,234...
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...